Abstract:Cisplatin is a platinum (Pt)-based anticancer drug with broad-scale clinical utility. However, due to its hydrophilic nature and high kinetic reactivity, it offers numerous drug delivery challenges. Limitations such as severe systemic toxicities, chemoresistance, extensive cisplatin-plasma protein interaction, and limited cellular drug uptake reduce the therapeutic impact of cisplatin therapy. Cisplatin(IV) prodrug formation can effectively resolve these challenges. The selection of axial ligands could play a key role in determining the fate of cisplatin(IV) prodrugs by modulating the therapeutic and biopharmaceutical outcomes of therapy. Hereby, three cisplatin(IV) derivatives were developed utilizing valproate, tocopherol, and chlorambucil as axial ligands, and their biopharmaceutical performance was compared along with cisplatin. The impact of cisplatin(IV) derivative formation on their kinetic stability, drug-albumin interaction, cytotoxicity profile, cellular uptake pattern, self-assembling behavior, hemotoxicity, and tumor biodistribution pattern was analyzed to establish the correlation between the structural properties of cisplatin(IV) agents and their biopharmaceutical outcomes. The kinetic inertness of the designed cisplatin(IV) compounds helped in minimizing their plasma protein interactions and ensuring their stability in the blood environment. The lipophilicity enhancement due to Pt(IV) prodrug formation critically helped in enhancing the cellular drug uptake and reduced the dependence on transporters for drug uptake. The lipophilicity and activity of axial ligands were the key drivers governing the biopharmaceutical performance of the Pt(IV) derivatives. The properties of the axial ligand, such as its therapeutic activity, chemical backbone, and functional groups present in its structure, were the critical factors determining their plasma protein interaction, cellular uptake, anticancer activity, and self-assembly pattern. Cisplatin(IV) derivative formation further improved the amount of platinum accumulated in tumors after intravenous injection compared to free cisplatin therapy (2.7-5.4 folds increment) and reduced drug-erythrocyte interactions. Overall, the results highlighted the potential of cisplatin(IV) agents in resolving cisplatin drug delivery challenges and denoted the critical role of axial ligand selection in Pt(IV) prodrug designing.

Pt( iv ) anticancer prodrugs bearing an oxaliplatin scaffold: what do we know about their bioactivity?

Pt(IV) Complexes in the Search for Novel Platinum Prodrugs with Promising Activity

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity

Multitargeted Platinum(IV) Anticancer Complexes Bearing Pyridinyl Ligands as Axial Leaving Groups.

Oxaliplatin(IV) Prodrugs Functionalized with Gemcitabine and Capecitabine Induce Blockage of Colorectal Cancer Cell Growth—An Investigation of the Activation Mechanism and Their Nanoformulation

Understanding the Role of Axial Ligands in Modulating the Biopharmaceutical Outcomes of Cisplatin(IV) Derivatives

Pt(IV) Prodrug Photoactivation: A Promising Strategy for Cancer Therapy

SBA‐15 Particles as Carriers for a series of Platinum(IV) Complexes with Oxaliplatin Scaffolds Bearing Different Anti‐Inflammatory Drugs: Promising Strategy Against Breast Cancer

Pt(IV) Prodrugs Containing Microtubule Inhibitors Displayed Potent Antitumor Activity and Ability to Overcome Cisplatin Resistance.

Synthesis, Reactivity Studies and Cytotoxicity of Two Iodidoplatinum(II) Complexes. Does Photoactivation Work?

Strategy to Regulate the Stability and Reduction Rate of Oxaliplatin-Based Pt(IV) Complexes: Cocrystallization

Rapid DNA interstrand cross-linking of Pt(IV) compound

Reversal of Cisplatin Resistance in Human Gastric Cancer Cells by a Wogonin-Conjugated Pt(IV) Prodrug Via Attenuating Casein Kinase 2-Mediated Nuclear Factor-κB Pathways.

Abplatin(IV) Inhibited Tumor Growth on a Patient Derived Cancer Model of Hepatocellular Carcinoma and Its Comparative Multi-Omics Study with Cisplatin

Berplatin: A Conjugate of Berberine and Cisplatin Serving As a Potent Antitumor Agent with Distinctive Tumor Cell Uptake and Minimal Side Effects

Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs

Platinum Drugs: from Pt(II) Compounds, Pt(IV) Prodrugs, to Pt Nanocrystals/nanoclusters.

Multifunctional Pt(iv) Complexes Containing a Glutathione S-transferase Inhibitor Lead to Enhancing Anticancer Activity and Preventing Metastasis of Osteosarcoma Cells

Ptxplatin: An multifunctional Pt(IV) antitumor prodrug

Recent Progresses in Conjugation with Bioactive Ligands to Improve the Anticancer Activity of Platinum Compounds

Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy